Citi keeps AUD 140.00 target for Cochlear stock ahead of AGM
Published on 10/24/2026 at 19:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and key dates
- Citi maintained a Hold rating and AUD 140.00 target on October 19, 2026.
- Cochlear's annual general meeting is scheduled for October 26, 2026, as a hybrid meeting.
- Fiscal 2027 underlying net profit guidance stands at AUD 330.00 million to AUD 350.00 million.
- Cochlear stock costs EUR 91.86 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Cochlear (AU000000COH5) remains under a Hold rating from Citi, which kept its AUD 140.00 price target in a report dated October 19, 2026, according to Markets Insider. At Lang & Schwarz, Cochlear stock was trading at EUR 91.86 on October 24, 2026 at 1:04 p.m. CEST.
AUD 140.00 target sets the reference point
The latest ASX quotation was AUD 146.81 on October 23, 2026 at 4:10 p.m. AEDT. Against that Australian price, Citi's AUD 140.00 target sits 4.64 percent below the stock. The calculation uses the target and the dated ASX quotation in the same currency.
UBS also maintained a Hold rating and an AUD 135.00 target in a report dated October 14, 2026, as reported by Markets Insider. The two targets place the latest broker view below the October 23 ASX price, while neither report changes the Hold stance.
AGM date arrives before the next update
Cochlear's 2026 annual general meeting is scheduled for October 26, 2026, in a hybrid format, according to The Globe and Mail. The meeting gives shareholders a dated corporate event after the recent analyst updates.
Recent commentary also points to fiscal 2027 earnings guidance. Motley Fool Australia reported that Cochlear's fiscal 2027 underlying net profit guidance was AUD 330.00 million to AUD 350.00 million after the fiscal 2026 results. That range is the next operating figure for investors to compare with the company's reported performance.
Price range leaves a wide trading frame
Cochlear's market capitalization was AUD 9.6 billion on October 23, 2026, while its 52-week range ran from AUD 88.74 to AUD 296.50. The stock's price-to-earnings ratio was 65.54 on the same dated quotation, placing the analyst targets below the latest Australian market price.
Cochlear develops implantable hearing solutions, including cochlear implants, sound processors and related accessories. Its primary listing is on the Australian Securities Exchange under ticker COH, while German investors receive the euro quotation through Lang & Schwarz.
Current quotation for German investors
The euro quotation stood at EUR 91.86 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The next dated event is Cochlear's hybrid annual general meeting on October 26, 2026.
The further course of trading is shown by the continuously updated real-time quote of Cochlear stock.
Cochlear stock at a glance
- Company: Cochlear Limited
- ISIN: AU000000COH5
- Ticker: COH
- Primary exchange: Australian Securities Exchange
- Price Lang & Schwarz as of October 24, 2026, 1:04 p.m. CEST: EUR 91.86
- Market capitalization: AUD 9.6 billion (as of October 23, 2026)
- 52-week range: AUD 88.74-296.50 (as of October 23, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report S&P/ASX 200.
